Mitigating supply risk: Having feet on the ground during COVID-19
Having personnel on the ground may be central to mitigating supply chain risks, even as the world embraces the remote approach.
Auditing remains a challenge for pharmaceutical companies, with pandemic-induced restrictions limiting their ability to conduct in-person inspections of contract manufacturing organisations (CMOs).
Health authorities and CMOs have been forced to adopt new processes for conducting audits, with many utilising a remote-first approach to avoid delays in the approval of new products or post-approval changes.
While remote audits are proving useful in bridging the gap caused by travel restrictions and social distancing measures, they do not come without their challenges and are not considered a replacement for inspections by the US Food and Drug Administration (FDA).
Issues related to technological availability and clear communication are compounded by the fact that not all pharmaceutical companies have local organisations in countries where their CMOs are based. Having qualified “feet on the ground” can prove advantageous in managing the audit process and ensuring compliance.
Nanjing Chemphar, a provider of pharmaceutical-related products and consulting services, has been assisting manufacturers with improving Good Manufacturing Practices (GMP) and Environmental Health & Safety (EHS) qualifications and helping them to pass US FDA, EU EDQM and Japan PMDA auditing.
Their QA Department works with local manufacturers to improve their GMP, with the goal of increasing customer satisfaction and creating sustainable sourcing.
Founded in 1975, Nanjing Chemphar handles the full supply chain as required by their customers around the world; from finding the most suitable factory, negotiating prices, final product quality assurance, insurance, shipping and delivery.
René Zoetmulder, a Partner at 4SCENERGY, described utilising Nanjing Chemphar’s services while leading the procurement organisation of a Netherlands-based pharmaceutical company during the COVID-19 pandemic.
Faced with sourcing risks compounded by regulatory constraints and obligations, he initiated a supply risk reduction program with a focus on security of supply, GMP and EHS.
He said: “During the first COVID-wave this company was, due to the professional team of Nanjing Chemphar, able to more than double the output of a drug that is used during ventilation of patients in IC, not having any production disruptions caused by the unavailability of the materials.”
Nanjing Chemphar recently started a partnership with 4SCENERGY, with the goal of enhancing support and reducing supply risks for overseas customers.
Related News
-
News Biotheus partners with BioNTech to take their anti-tumour therapy global
Innovative biotech company Biotheus has signed a deal with BioNTech to manufacture, market, and distribute their latest anti-tumour therapy around the world. -
News Roche acquires rights to Zion Pharma's HER2-positive breast cancer therapeutic
Roche launches into a new agreement with Zion Pharma, a leading Chinese pharmaceutical company, to help develop and commercialise their flagship small molecule tyrosine kinase inhibitor, ZN-A-1041. -
News 2023 Lunar New Year Round-up: Biopharma in the APAC region
With the Lunar New Year ushering in celebrations for the pharmaceutical community around the world on Sunday January 22, 2023, we’ve rounded up some of the top CPHI Online articles and reports from the last year looking at pharmaceutical markets ... -
News Lonza start commercial operations in newly expanded facility
Lonza Small Molecules adds new capabilities to their expanded facility in China, enabling smoother transitions between small and large scale manufacturing. -
News Thermo Fisher Scientific expands with state-of-the-art facility in China
Thermo Fisher Scientific are to open a new cGMP facility in China, including the latest technology so that they can assist in the accelerated provision of medicines to patients. -
News Chinese market represents ‘single greatest generational opportunity’ for Pharma
China’s pharmaceutical industry is changing from formerly generics-focused into one that emphasizes innovation, spurred by shifting government policy and an aging population. -
News Sharp seeks greater foothold in Chinese market through ClinsChain partnership
Sharp hopes teaming up with clinical service provider ClinsChain will open the door to the Chinese market -
News WuXi STA launches new HPAPI production facility in China
The new plant features flow chemistry and milling technology, as well as reactors up to 3,000 liters
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance